|
Recommended Books on Vitamin B12
The 2007-2012 Outlook for Oral Hematinics Excluding Vitamin B12 in Greater China This study covers the latent demand outlook for oral hematinics excluding vitamin B12 across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as regions). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of economic population, as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this economic definition of population, comparative benchmarks allow the reader to quickly gauge a citys marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for oral hematinics excluding vitamin B12. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
The 2007-2012 Outlook for Vitamin B12 Oral Hematinics in Greater China This study covers the latent demand outlook for vitamin B12 oral hematinics across the regions of Greater China, including provinces, autonomous regions (Guangxi, Nei Mongol, Ningxia, Xinjiang, Xizang - Tibet), municipalities (Beijing, Chongqing, Shanghai, and Tianjin), special administrative regions (Hong Kong and Macau), and Taiwan (all hereafter referred to as regions). Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,100 cities in Greater China. For each major city in question, the percent share the city is of the region and of Greater China is reported. Each major city is defined as an area of economic population, as opposed to the demographic population within a legal geographic boundary. For many cities, the economic population is much larger that the population within the city limits; this is especially true for the cities of the Western regions. For the coastal regions, cities which are close to other major cities or which represent, by themselves, a high percent of the regional population, actual city-level population is closer to the economic population (e.g. in Beijing). Based on this economic definition of population, comparative benchmarks allow the reader to quickly gauge a citys marketing and distribution value vis-à-vis others. This exercise is quite useful for persons setting up distribution centers or sales force strategies. Using econometric models which project fundamental economic dynamics within each region and city of influence, latent demand estimates are created for vitamin B12 oral hematinics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
The 2007-2012 Outlook for Vitamin B12 Oral Hematinics in India This study covers the latent demand outlook for vitamin B12 oral hematinics across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,700 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for vitamin B12 oral hematinics. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
The 2007-2012 Outlook for Oral Hematinics Excluding Vitamin B12 in the United States This study covers the latent demand outlook for oral hematinics excluding vitamin B12 across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 5,700 cities in the United States. For each city in question, the percent share the city is of its state and of the United States is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for oral hematinics excluding vitamin B12. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
The 2007-2012 Outlook for Oral Hematinics Excluding Vitamin B12 in India This study covers the latent demand outlook for oral hematinics excluding vitamin B12 across the states, union territories and cities of India. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,900 cities in India. For each city in question, the percent share the city is of its state or union territory and of India as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state or union territory and city, latent demand estimates are created for oral hematinics excluding vitamin B12. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
The 2007-2012 Outlook for Oral Hematinics Excluding Vitamin B12 in Japan This study covers the latent demand outlook for oral hematinics excluding vitamin B12 across the prefectures and cities of Japan. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 1,000 cities in Japan. For each city in question, the percent share the city is of its prefecture and of Japan is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each prefecture and city, latent demand estimates are created for oral hematinics excluding vitamin B12. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.
Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline (Dietary Reference Series) Since 1941, Recommended Dietary Allowances (RDAs) has been recognized as the most authoritative source of information on nutrient levels for healthy people. Since publication of the 10th edition in 1989, there has been rising awareness of the impact of nutrition on chronic disease. In light of new research findings and a growing public focus on nutrition and health, the expert panel responsible for formulation RDAs reviewed and expanded its approach--the result: Dietary Reference Intakes. This new series of references greatly extends the scope and application of previous nutrient guidelines. For each nutrient the book presents what is known about how the nutrient functions in the human body, what the best method is to determine its requirements, which factors (caffeine or exercise, for example) may affect how it works, and how the nutrient may be related to chronic disease. This volume of the series presents information about thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Based on analysis of nutrient metabolism in humans and data on intakes in the U.S. population, the committee recommends intakes for each age group--from the first days of life through childhood, sexual maturity, midlife, and the later years. Recommendations for pregnancy and lactation also are made, and the book identifies when intake of a nutrient may be too much. Representing a new paradigm for the nutrition community, Dietary Reference Intakes encompasses: Estimated Average Requirements (EARs). These are used to set Recommended Dietary Allowances. Recommended Dietary Allowances (RDAs). Intakes that meet the RDA are likely to meet the nutrient requirement of nearly all individuals in a life-stage and gender group. Adequate Intakes (AIs). These are used instead of RDAs when an EAR cannot be calculated. Both the RDA and the AI may be used as goals for individual intake. Tolerable Upper Intake Levels (ULs). Int
Could It Be B12?: An Epidemic of Misdiagnoses In Could It Be B12?, RN Sally M. Pacholok and her physician husband, Jeffrey J. Stuart, cite the extensive research done by numerous medical centers and universities that proves B12 deficiency plays a defining role in many seemingly hopeless problems.
Yet, even in the face of these studies, this disorder has somehow been overlooked by the general medical field and is often misdiagnosed.
The authors include numerous case histories and offer their readers strategies on how to learn if they or a loved one may be suffering from a B12 deficiency.
Homocysteine. Related Vitamins and Neuropsychiatric Disorders During the last 15 years the research on homocysteine and the vitamins involved in its metabolism has become very dynamic. About 1,500 publications on the subject are now published each year. The research has long mainly focused on the association between homocysteine and cardiovascular disease, but also pregnancy complications/ fetal malformations. There is, however, an increasing interest in the connection between the homocysteine metabolism and neuropsychiatric disease with a steeply increasing number of publications. In particular, the association between homocysteine metabolism and cognitive decline/dementia attracts much interest. If simple, non-toxic homocysteine-lowering treatment with vitamins can reduce the incidence of, or delay the onset of dementia, it would have an enormous impact in societies with a rapidly increasing number of elderly at risk for dementia. This book summarises the research within the neuropsychiatric field, but also gives an overview of the underlying biochemistry and of diagnostic aspects. About 1,000 references are given. Christina Bolander-Gouaille, a pharmacist, has for over 10 years specialised in writing reviews/monographs on homocysteine and related vitamins. This is her third book in a series edited by Springer Verlag. This book, however, is written in collaboration with Teodoro Bottiglieri, who is director of neuropharmacology and senior research scientist at Baylor University, Institute for Metabolic Diseases in Dallas, USA.
Focus on Homocysteine and the Vitamins Involved in Its Metabolism During the last 10-12 years, the research on homocysteine has become very active. About 1500 of articles are now published each year on homocysteine and the vitamins involved in its metabolism. A disturbed homocysteine metabolism can be an underlying factor for pregnancy complications and fetal malformations, cardiovascular disease, dementia, psychiatric and neurologic disorders and possibly carcinogenesis. A disturbed homocysteine metabolism can in most cases be normalised by treatment with folate and/or vitamines B12 and B6. Many of these findings therefore directly concern most practitioners. However, if there are good reviews covering single aspects of this research, these are published in specialised journals. The author has realised the difficulties for the practitioner in keeping updated. This second edition has been thoroughly updated and also offers more data on the vitamins. Over 1600 references are made available.
© 2004-2008 Vitamin B12 Research Today. All Rights Reserved.
|
|
